565 results on '"Mohler, Emile R."'
Search Results
552. Drug treatment of intermittent claudication.
- Author
-
Jacoby D and Mohler ER 3rd
- Subjects
- Animals, Cilostazol, Clinical Trials as Topic, Humans, Pentoxifylline administration & dosage, Pentoxifylline adverse effects, Tetrazoles administration & dosage, Tetrazoles adverse effects, Treatment Outcome, Vasodilator Agents administration & dosage, Vasodilator Agents adverse effects, Intermittent Claudication drug therapy, Pentoxifylline therapeutic use, Tetrazoles therapeutic use, Vasodilator Agents therapeutic use
- Abstract
The US FDA has approved two drugs for the management of intermittent claudication: pentoxifylline and cilostazol. The mechanism of action that provides symptom relief with pentoxifylline is poorly understood but is thought to involve red blood cell deformability as well as a reduction in fibrinogen concentration, platelet adhesiveness and whole blood viscosity. The recommended dose of pentoxifylline is 400 mg three times daily with meals. Cilostazol is a potent, reversible, phosphodiesterase III inhibitor. The inhibition of phosphodiesterase allows for the increased availability of cyclic adenosine monophosphate (cAMP). cAMP mediates many agonist-induced platelet inhibitory, vasodilatory and vascular antiproliferative responses. Cilostazol, at a dose of 100 mg twice daily, is recommended to be taken 30 minutes before or 2 hours after breakfast and dinner. In addition to pentoxifylline and cilostazol, clinical trials indicate many other drugs may relieve the symptoms of intermittent claudication. Ginkgo biloba, available as an over-the-counter extract, provides symptom relief comparable to pentoxifylline. Two European agents, naftidrofuryl and buflomedil, also have efficacy that is reported to be similar to pentoxifylline. Policosanol is a mixture of fatty alcohols derived from honeybee wax which, according to very limited data, reduces symptoms of claudication. Amino acids, certain peptides and prostaglandins may have a therapeutic role. Finally, novel approaches including angiogenesis mediated by growth factors, are currently under investigation.
- Published
- 2004
- Full Text
- View/download PDF
553. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial.
- Author
-
Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, and Mohler ER 3rd
- Subjects
- Adult, Aged, Aged, 80 and over, Angiography, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gadolinium, Humans, Male, Middle Aged, Peripheral Vascular Diseases diagnostic imaging, ROC Curve, Safety, Contrast Media, Magnetic Resonance Angiography, Organometallic Compounds adverse effects, Peripheral Vascular Diseases diagnosis
- Abstract
Purpose: To evaluate the dose response and safety of gadofosveset trisodium-enhanced magnetic resonance (MR) angiography compared with nonenhanced two-dimensional time-of-flight MR angiography and with x-ray angiography as the standard., Materials and Methods: In this randomized, 20-center, double-blind study, 238 men and women who had peripheral vascular disease or were suspected of having it received intravenous injection of placebo or gadofosveset (0.005, 0.01, 0.03, 0.05, or 0.07 mmol per kilogram of body weight). MR angiographic images were evaluated by three blinded readers, and x-ray angiographic images were evaluated by two readers. Hypothesis testing for the presence of a dose response was based on a linear test for trend for increase in area under the receiver operating characteristic curve as a function of dose for each reader of MR angiographic images independently., Results: Gadofosveset administration resulted in a dose-dependent increase in diagnostic accuracy for detection of aortoiliac occlusive disease as reflected in the area under the receiver operating characteristic curve for each reader (P <.001). The plateau in effectiveness improvement began at the 0.03 mmol/kg dose. At doses of 0.03 mmol/kg and higher, gadofosveset-enhanced MR angiography provided an approximate 20% increase in accuracy over nonenhanced MR angiography for diagnosis of clinically significant aortoiliac occlusive disease. Gadofosveset exhibited a good safety profile in all dose groups. Three serious adverse events were possibly or probably related to gadofosveset administration. There were no dose-related trends in severe or serious adverse events in patients receiving gadofosveset., Conclusion: A dose of 0.03 mmol/kg of gadofosveset was safe and effective for evaluation of aortoiliac occlusive disease with MR angiography.
- Published
- 2003
- Full Text
- View/download PDF
554. Images in vascular medicine. Distal abdominal aortic occlusion.
- Author
-
Chen D and Mohler ER 3rd
- Subjects
- Adult, Aortic Diseases physiopathology, Arterial Occlusive Diseases physiopathology, Female, Humans, Radiography, Walking physiology, Aorta, Abdominal diagnostic imaging, Aortic Diseases diagnostic imaging, Arterial Occlusive Diseases diagnostic imaging
- Published
- 2003
- Full Text
- View/download PDF
555. Peripheral arterial disease: identification and implications.
- Author
-
Mohler ER 3rd
- Subjects
- Diagnosis, Differential, Disease Progression, Exercise Test, Exercise Therapy, Humans, Peripheral Vascular Diseases mortality, Peripheral Vascular Diseases therapy, Physical Examination, Platelet Aggregation Inhibitors therapeutic use, Peripheral Vascular Diseases diagnosis
- Abstract
Peripheral arterial disease (PAD) is most commonly a manifestation of systemic atherosclerosis in which the arterial lumen of the lower extremities becomes progressively occluded by atherosclerotic plaque. Patients with PAD are at triple the risk of all-cause mortality and at more than 6 times the risk of death from coronary heart disease as those without the disease, yet PAD is probably the most underdiagnosed and least aggressively managed atherosclerotic disease. In the diagnosis of PAD, a detailed history and physical examination are extremely important, although limited by a lack of consistent sensitivity and specificity. Other office-based noninvasive tests, including the ankle-brachial index, can be easily performed to confirm the diagnosis and help stratify the risk. The ankle-brachial index correlates well with disease severity and functional symptoms and can also be used to assess disease progression and to predict cardiovascular and cerebrovascular mortality. Once diagnosed, risk factor modification, symptomatic relief, and secondary prevention strategies with antiplatelet agents form the core of medical management of PAD.
- Published
- 2003
- Full Text
- View/download PDF
556. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
- Author
-
Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, and Annex BH
- Subjects
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Edema chemically induced, Endothelial Growth Factors adverse effects, Endothelial Growth Factors genetics, Female, Genetic Therapy adverse effects, Genetic Therapy methods, Humans, Intercellular Signaling Peptides and Proteins adverse effects, Intercellular Signaling Peptides and Proteins genetics, Intermittent Claudication etiology, Intermittent Claudication therapy, Lymphokines adverse effects, Lymphokines genetics, Male, Middle Aged, Peripheral Vascular Diseases complications, Quality of Life, Treatment Outcome, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors, Walking statistics & numerical data, Adenoviridae genetics, Endothelial Growth Factors administration & dosage, Genetic Vectors administration & dosage, Intercellular Signaling Peptides and Proteins administration & dosage, Lymphokines administration & dosage, Neovascularization, Physiologic drug effects, Peripheral Vascular Diseases therapy
- Abstract
Background: "Therapeutic angiogenesis" seeks to improve perfusion by the growth of new blood vessels. The Regional Angiogenesis with Vascular Endothelial growth factor (RAVE) trial is the first major randomized study of adenoviral vascular endothelial growth factor (VEGF) gene transfer for the treatment of peripheral artery disease (PAD)., Methods and Results: This phase 2, double-blind, placebo-controlled study was designed to test the efficacy and safety of intramuscular delivery of AdVEGF121, a replication-deficient adenovirus encoding the 121-amino-acid isoform of vascular endothelial growth factor, to the lower extremities of subjects with unilateral PAD. In all, 105 subjects with unilateral exercise-limiting intermittent claudication during 2 qualifying treadmill tests, with peak walking time (PWT) between 1 to 10 minutes, were stratified on the basis of diabetic status and randomized to low-dose (4x10(9) PU) AdVEGF121, high-dose (4x10(10) PU) AdVEGF121, or placebo, administered as 20 intramuscular injections to the index leg in a single session. The primary efficacy end point, change in PWT (DeltaPWT) at 12 weeks, did not differ between the placebo (1.8+/-3.2 minutes), low-dose (1.6+/-1.9 minutes), and high-dose (1.5+/-3.1 minutes) groups. Secondary measures, including DeltaPWT, ankle-brachial index, claudication onset time, and quality-of-life measures (SF-36 and Walking Impairment Questionnaire), were also similar among groups at 12 and 26 weeks. AdVEGF121 administration was associated with increased peripheral edema., Conclusions: A single unilateral intramuscular administration of AdVEGF121 was not associated with improved exercise performance or quality of life in this study. This study does not support local delivery of single-dose VEGF121 as a treatment strategy in patients with unilateral PAD.
- Published
- 2003
- Full Text
- View/download PDF
557. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
- Author
-
Mohler ER 3rd, Hiatt WR, and Creager MA
- Subjects
- Aged, Anticholesteremic Agents adverse effects, Atorvastatin, Double-Blind Method, Exercise Test, Exercise Tolerance drug effects, Female, Heptanoic Acids adverse effects, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Intermittent Claudication drug therapy, Intermittent Claudication etiology, Male, Peripheral Vascular Diseases complications, Prospective Studies, Pyrroles adverse effects, Quality of Life, Treatment Outcome, Walking, Anticholesteremic Agents therapeutic use, Cholesterol blood, Heptanoic Acids therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Peripheral Vascular Diseases drug therapy, Pyrroles therapeutic use
- Abstract
Background: Cholesterol modification reduces cardiovascular events in patients with atherosclerosis, including those with peripheral arterial disease. The purpose of this study was to determine whether cholesterol lowering with atorvastatin improves walking performance in patients with intermittent claudication., Methods and Results: This randomized, double-blind, parallel-design study included 354 persons with claudication attributable to peripheral arterial disease. Patients were treated with placebo, atorvastatin (10 mg per day), or atorvastatin (80 mg per day) for 12 months. The outcome measures included change in treadmill exercise time and patient-reported measures of physical activity and quality of life based on questionnaires. Maximal walking time after 12 months of treatment with atorvastatin did not change significantly. However, there was improvement in pain-free walking time after 12 months of treatment for the 80-mg (P=0.025) group compared with placebo. A physical activity questionnaire demonstrated improvement in ambulatory ability for the 10- and 80-mg groups (P=0.011), whereas 2 quality of life instruments, the Walking Impairment Questionnaire and Short Form 36 Questionnaire, did not show significant change., Conclusions: Atorvastatin improves pain-free walking distance and community-based physical activity in patients with intermittent claudication. When treated with atorvastatin, patients with peripheral arterial disease may experience improvement in symptoms to complement the anticipated reduction in cardiovascular events reported in other studies of statins.
- Published
- 2003
- Full Text
- View/download PDF
558. Brachial artery: measurement of flow-mediated dilatation with cross-sectional US--technical validation.
- Author
-
Kao YH, Mohler ER, Arger PH, and Sehgal CM
- Subjects
- Algorithms, Humans, Phantoms, Imaging, Pulsatile Flow physiology, Sensitivity and Specificity, Ultrasonography, Vasodilation physiology, Brachial Artery diagnostic imaging, Brachial Artery physiology
- Abstract
Ultrasonographic examination of flow phantoms and the brachial artery of a healthy volunteer undergoing reactive hyperemia was performed. Images were analyzed with a user-guided automated boundary detection (UGABD) algorithm to extract boundaries and measure cross-sectional area. UGABD correctly detected pulsatile vasomotion and measured area within 5% of the true value. A comparison of UGABD versus manual tracing yielded linear correlation of 0.81-0.91. Peak vasodilatation measured in response to reactive hyperemia was 150 times greater in pixel count than that measured with longitudinal imaging. Cross-sectional imaging is more sensitive than longitudinal imaging for measuring flow-mediated dilatation of the brachial artery.
- Published
- 2003
- Full Text
- View/download PDF
559. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods.
- Author
-
Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, and Wright JT
- Subjects
- Adult, Age Distribution, Aged, Female, Humans, Incidence, Kidney Failure, Chronic therapy, Kidney Function Tests, Male, Middle Aged, Patient Selection, Prognosis, Renal Dialysis statistics & numerical data, Research Design, Risk Assessment, Severity of Illness Index, Sex Distribution, Survival Rate, United States epidemiology, Kidney Failure, Chronic epidemiology
- Abstract
Insights into end-stage renal disease have emerged from many investigations but less is known about the epidemiology of chronic renal insufficiency (CRI) and its relationship to cardiovascular disease (CVD). The Chronic Renal Insufficiency Cohort (CRIC) Study was established to examine risk factors for progression of CRI and CVD among CRI patients and develop models to identify high-risk subgroups, informing future treatment trials, and increasing application of preventive therapies. CRIC will enroll approximately 3000 individuals at seven sites and follow participants for up to 5 yr. CRIC will include a racially and ethnically diverse group of adults aged 21 to 74 yr with a broad spectrum of renal disease severity, half of whom have diagnosed diabetes mellitus. CRIC will exclude subjects with polycystic kidney disease and those on active immunosuppression for glomerulonephritis. Subjects will undergo extensive clinical evaluation at baseline and at annual clinic visits and via telephone at 6 mo intervals. Data on quality of life, dietary assessment, physical activity, health behaviors, depression, cognitive function, health care resource utilization, as well as blood and urine specimens will be collected annually. (125)I-iothalamate clearances and CVD evaluations including a 12-lead surface electrocardiogram, an echocardiogram, and coronary electron beam or spiral CT will be performed serially. Analyses planned in CRIC will provide important information on potential risk factors for progressive CRI and CVD. Insights from CRIC should lead to the formulation of hypotheses regarding therapy that will serve as the basis for targeted interventional trials focused on reducing the burden of CRI and CVD.
- Published
- 2003
- Full Text
- View/download PDF
560. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis.
- Author
-
Jian B, Narula N, Li QY, Mohler ER 3rd, and Levy RJ
- Subjects
- Aged, Aged, 80 and over, Alkaline Phosphatase metabolism, Amino Acid Chloromethyl Ketones pharmacology, Animals, Aortic Valve chemistry, Aortic Valve Stenosis pathology, Apoptosis physiology, Caspase Inhibitors, Cells, Cultured, Disease Progression, Female, Humans, Immunohistochemistry, Male, Sheep, Transforming Growth Factor beta metabolism, Transforming Growth Factor beta1, Aortic Valve Stenosis physiopathology, Calcinosis physiopathology, Transforming Growth Factor beta physiology
- Abstract
Background: Aortic valve stenosis characteristically progresses due to cuspal calcification, often necessitating valve replacement surgery. The present study investigated the hypothesis that TGF-beta1, a cytokine that causes calcification of vascular smooth muscle cells in culture, initiates apoptosis of valvular interstitial cells as a mechanistic event in cuspal calcification., Methods: Noncalcified and calcified human aortic valve cusps were obtained at autopsy or at the time of cardiac surgery. The distributions within cusps of TGF-beta1, latent-TGF-beta1-associated peptide, and TGF-beta receptors were studied using immunohistochemistry. The effects of TGF-beta1 on mechanistic events contributing to aortic valve calcification were also investigated using sheep aortic valve interstitial cell (SAVIC) cultures., Results: Immunohistochemistry studies revealed that calcific aortic stenosis cusps characteristically contained within the extracellular matrix qualitatively higher levels of TGF-beta1 than noncalcified cusps. Noncalcified normal valves demonstrated only focal intracellular TGF-beta1. Addition of TGF-beta1 to SAVIC cultures led to a cascade of events, including: cellular migration, aggregation, formation of apoptotic-alkaline phosphatase enriched nodules, and calcification of these nodules. The time course of these events in the SAVIC culture system was rapid with nodule formation with apoptosis by 72 hours, and calcification after 7 days. Furthermore, ZVAD-FMK, an antiapoptosis agent (caspase inhibitor), significantly inhibited calcification and apoptosis induced by TGF-beta1, but had no effect on nodule formation. However, cytochalasin D, an actin-depolymerizing agent, inhibited nodule formation, but not calcification., Conclusions: TGF-beta1 is characteristically present within calcific aortic stenosis cusps, and mediates the calcification of aortic valve interstitial cells in culture through mechanisms involving apoptosis.
- Published
- 2003
- Full Text
- View/download PDF
561. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.
- Author
-
Mohler ER 3rd, Rajagopalan S, Olin JW, Trachtenberg JD, Rasmussen H, Pak R, and Crystal RG
- Subjects
- Adult, Aged, Aged, 80 and over, Angiogenesis Inducing Agents administration & dosage, Angiogenic Proteins administration & dosage, Dose-Response Relationship, Drug, Double-Blind Method, Endothelial Growth Factors administration & dosage, Female, Genetic Vectors administration & dosage, Genetic Vectors genetics, Genetic Vectors therapeutic use, Humans, Lymphokines administration & dosage, Male, Middle Aged, Protein Isoforms administration & dosage, Protein Isoforms genetics, Protein Isoforms therapeutic use, Vascular Endothelial Growth Factor A administration & dosage, Adenoviridae genetics, Angiogenesis Inducing Agents therapeutic use, Angiogenic Proteins genetics, Angiogenic Proteins therapeutic use, Endothelial Growth Factors genetics, Endothelial Growth Factors therapeutic use, Gene Transfer Techniques, Ischemia drug therapy, Ischemia genetics, Lower Extremity blood supply, Lymphokines genetics, Lymphokines therapeutic use, Peripheral Vascular Diseases drug therapy, Peripheral Vascular Diseases genetics, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A therapeutic use
- Abstract
Critical limb ischemia (CLI) is typified by rest pain and/or tissue necrosis secondary to advanced peripheral arterial disease (PAD) and is characterized by diminution in limb perfusion at rest. We tested the safety of an angiogenic strategy with CI-1023 (Ad(GV)VEGF121.10), a replication-deficient adenovirus encoding human vascular endothelial growth factor isoform 121 in patients with CLI as part of a phase I trial. Fifteen subjects >35 years of age with CLI and angiographic disease involving the infra-inguinal vessels underwent intramuscular injection of CI-1023 (4 x 10(8) to 4 x 10(10) particle units, n = 13) or placebo (n = 2). All of the patients tolerated the injection well and there were no serious complications related to the procedure. Transient edema was noted in one patient. A total of 79 adverse events were reported over the course of one year. One death (day 136) and one malignancy (day 332) occurred in the CI-1023 group. CI-1023 appears to be well tolerated and safe for single-dose administration in patients with critical limb ischemia due to PAD. Further studies are needed to determine the efficacy of this form of therapeutic angiogenesis.
- Published
- 2003
- Full Text
- View/download PDF
562. A novel ultrasound method for evaluation of collateral development in limb ischemia.
- Author
-
Mohler ER 3rd, Sehgal CM, Ferrari VA, Parmacek M, Shih A, and Wilensky RL
- Subjects
- Animals, Blood Pressure physiology, Capillaries diagnostic imaging, Capillaries physiopathology, Disease Models, Animal, Male, Radiography, Regional Blood Flow physiology, Swine, Time Factors, Collateral Circulation physiology, Forelimb blood supply, Forelimb diagnostic imaging, Hindlimb blood supply, Hindlimb diagnostic imaging, Ischemia diagnosis, Ischemia physiopathology, Ultrasonography, Doppler, Color
- Abstract
Although clinical studies are underway to evaluate the effectiveness of angiogenesis, there are no validated, non-invasive methods to assess peripheral collateral development. This study was performed to validate a novel ultrasound-based method of assessing collateral formation in a pig model of hindlimb ischemia. Ultrasonography of predefined ultrasound planes was performed on 12 pigs immediately after ligation of the right common femoral artery, and 7, 14, 28 and 42 days thereafter. A custom software program was used to evaluate both color Doppler (CD) and power Doppler (PD) images to generate flow indices. Collateral development was observed with ultrasound as early as 7 days post-arteriectomy and increased dramatically by 28 days. Areas of persistent ischemia resulting from inadequate collateral formation were easily quantified in all images. Collaterals detected on ultrasound were confirmed by angiography and histology, and tissue perfusion by a fluorescent microsphere method. As demonstrated with color and power Doppler measurements, collateral formation is initiated early after ischemic injury in this large juvenile animal model of angiogenesis. This non-invasive method is useful to quantify blood flow, visualize angiogenesis and determine areas of persistent lower limb ischemia, and may have an important role in evaluating new approaches to modulate angiogenesis.
- Published
- 2002
- Full Text
- View/download PDF
563. Vascular calcification: good, bad or ugly?
- Author
-
Mohler ER 3rd
- Subjects
- Calcinosis diagnosis, Calcinosis physiopathology, Clinical Trials as Topic, Coronary Artery Disease etiology, Coronary Artery Disease pathology, Coronary Artery Disease physiopathology, Humans, Lipid Peroxidation physiology, Lipoproteins, LDL physiology, Vascular Diseases pathology, Vascular Diseases physiopathology, Calcinosis etiology, Vascular Diseases etiology
- Published
- 2002
- Full Text
- View/download PDF
564. Bone formation in carotid plaques: a clinicopathological study.
- Author
-
Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, Khalapyan T, Wolfe M, Neschis D, Milner R, Scoll B, Cusack A, and Mohler ER 3rd
- Subjects
- Adult, Aged, Aged, 80 and over, Arteriosclerosis complications, Calcinosis complications, Carotid Stenosis complications, Carotid Stenosis surgery, Demography, Endarterectomy, Carotid, Female, Humans, Immunohistochemistry, Ischemic Attack, Transient complications, Male, Middle Aged, Prospective Studies, Risk Factors, Stroke complications, Arteriosclerosis pathology, Calcinosis pathology, Carotid Stenosis pathology, Osteogenesis
- Abstract
Background and Purpose: Bone formation and dystrophic calcification are present in carotid endarterectomy plaques. The clinical significance of these findings is unknown. The purpose of this study was to determine whether bone formation and extensive dystrophic calcification are associated with stable plaques and protective against ischemic vascular events., Methods: Carotid endarterectomy plaques were collected from 142 patients (94 men) with carotid stenosis. The specimens were evaluated for lamellar bone formation, dystrophic calcifications, inflammatory infiltrates, neovascularization, and histological type or grade of plaque according to a standard AHA grading system. Immunohistochemical staining was performed to identify vascular endothelial cells in neovascularization (factor VIII) and lymphocytes. Clinical data, including history of cerebrovascular and cardiovascular events, were recorded at the time of surgery., Results: Patients with calcification of carotid plaques had fewer symptoms of stroke and transient ischemic attack (P=0.042) than those without calcification. Stroke and transient ischemic attack occurred less frequently in patients with plaques with large calcific granules (P=0.021). Of the patients, 13% had lamellar bone formation, which directly correlated with the presence of sheetlike calcifications (P=0.0001) and inversely correlated with ulcerated lesions (P=0.048). The presence of bone also correlated with diabetes (P<0.01) and coronary artery disease (P<0.01). Of the 20 patients with bone, 6 had a history of stoke and transient ischemic attack (P=0.5)., Conclusions: The results indicate that bone formation tends to occur in heavily calcified carotid lesions devoid of ulceration and hemorrhage. Patients with extensive calcification of the carotid plaques are less likely to have symptomatic disease.
- Published
- 2002
- Full Text
- View/download PDF
565. Splenic artery aneurysm.
- Author
-
Shih A, Golden M, and Mohler ER 3rd
- Subjects
- Aged, Humans, Male, Rupture, Spontaneous diagnosis, Splenic Artery diagnostic imaging, Tomography, X-Ray Computed, Aneurysm diagnosis, Aneurysm, Ruptured diagnosis, Splenic Artery pathology
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.